Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: olivier benrubi who wrote (590)	3/10/2005 3:20:30 PM
From: tuck	Read Replies (2) of 946

>>Wouldn't a fair proportion of Stellar 2 patients be Pac resistant as they are second line ?<< Not sure. It's 2nd line treatment, indeed, and patients are required to have had a year of platinum therapy. While the protocol doesn't specifically exclude paclitaxel patients (specifically excludes PEG paclitaxel), I don't see how they could be in there unless maybe they were on a doublet of paclitaxel and platinum. That's possible, certainly, I'm not sure how common that doublet is now. The protocol says patients will be stratified on the basis of prior taxane therapy, which is a good thing, because there isn't much cross-resistance between docetaxel and paclitaxel. If they are a large part, you're right that it could be a problem, as the subset of patients not resistant might not be large enough for good power. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next